TRex Bio
Erwin was a 36-year veteran at Lilly, recently as vice president of corporate business development for the Big Pharma's venture portfolio.
Erwin helped found the company three years ago while helping manage Lilly's venture capital operation and decided to rejoin TRexBio as CEO in 2021 because of its science, the team of discovery scientists and a platform of more than 20 new tissue-focused targets.
This person is not in any offices
TRex Bio
TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases.